A molecular test can pinpoint which patients will have a very low risk of death from breast cancer even 20 years after diagnosis and tumor removal, according to a new clinical study. As a result, ‘ultralow’ risk patients could be treated less aggressively and overtreatment avoided, leading to fewer toxic effects.